Early Invasive Strategy Benefits High-Risk Patients

Early angiography is not associated with a reduction in mortality compared with a more delayed invasive strategy in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). However, a new meta-analysis published by The Lancet supports the idea that certain high-risk patients would benefit from it.

La estrategia invasiva precoz beneficia a los pacientes de alto riesgo

Patients with elevated cardiac biomarkers, a high GRACE score, diabetes, or advanced age might obtain a decrease in their mortality rate with early angiography, as opposed to a delayed strategy.

 

This benefit as regards mortality had not been proved, thus perpetuating over time the debate on the optimal moment to bring patients with NSTE-ACS to the cath lab. Furthermore, both American and European guidelines timidly recommend studying patients with elevated troponin levels or a GRACE score >140 within the first 24 hours.


Read also: Follow-up at 10 years for invasive vs. conservative strategy for non-ST-segment elevation infarction”.


It should be acknowledged that the outcome of this meta-analysis as regards the global population was neutral. In consequence, this benefit as regards mortality for these specific risk sub-groups should be considered as a hypothesis to be tested in future studies.

 

The meta-analysis recently published in The Lancet included 8 studies with over 5300 patients. The range of angiography timing was wide among works, from the ABOARD study, in which patients were brought to the cath lab immediately, to the TIMACS study, in which early strategy was defined as that implemented within 24 hours.

 

Similarly, the range of delayed invasive strategy timing was also wide, from the ABOARD study, in which all patients were studied at the following work day, to studies that allowed for up to 72 hours from the onset of symptoms. The mean follow-up, considering all studies, was 180 days.


Read also: CTO in patients with acute myocardial infarction increases long term mortality”.


Globally, there was no significant reduction in mortality among patients randomized to an early invasive strategy vs. a delayed invasive strategy (hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.64-1.03).

 

However, in the pre-specified analysis of high-risk patients, there was lower mortality in patients with elevated troponin (HR: 0.76; 95% CI: 0.58-1.00), diabetes (HR: 0.67; 95% CI: 0.45-0.99), a GRACE score >140 (HR: 0.70; 95% CI: 0.52-0.95), and aged 75 years or older (HR: 0.65; 95% CI: 0.46-0.93).

 

European guidelines recommend invasive angiography within 24 hours for high-risk patients with NSTE-ACS, and within 72 hours for intermediate-risk patients. Immediate invasive strategy is recommended only for extremely-high-risk patients, such as those with refractory angina or hemodynamic instability. ACC/AHA guidelines recommend similar management options, and that is as far as evidence goes. This meta-analysis presents too many limitations to become the foundations for a guideline update.

 

The eight studies included randomized patients from 2000 to 2016, which represents a long time interval. Anti-platelet drugs have evolved, stents have evolved, biomarker analysis has evolved, and there will be no definitive conclusion without a new study comparing early invasive strategy vs. delayed invasive strategy in patients with non-ST-elevation acute coronary syndrome.

 

Original title: Optimal Timing of an Invasive Strategy in Patients with Non-ST-Elevation Acute Coronary Syndrome: A Meta-Analysis of Randomised Trials.

Reference: Jobs A et al. Lancet. 2017; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...